S1P-Mediated Stimulation of Antimicrobial Defense

S1P 介导的抗菌防御刺激

基本信息

  • 批准号:
    8666523
  • 负责人:
  • 金额:
    $ 32.68万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-08-01 至 2017-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Atopic dermatitis (AD) skin displays epidermal permeability as well as antimicrobial deficiency, and is often colonized with virulent S. aureus. Ceramide (Cer) is both an essential permeability barrier lipid species and a bioeffector that alters multiple cellular functions in nucleated epidermal keratinocytes (KC). Importantly, a distal metabolite of Cer, sphingosine-1-phosphate (S1P) also modulates cellular functions, and levels of both Cer and S1P are reduced in AD. Pertinent to this proposal, AD epidermis shows a failure to upregulate a major epidermal cathelicidin antimicrobial peptide (CAMP)/LL-37 expression, which could account for S. aureus colonization and persistence in AD. We recently demonstrated that S1P stimulates CAMP expression not only through the well-characterized vitamin D receptor (VDR)-dependent mechanism, but also by a NF-?B-C/EBP¿-dependent pathway that is independent of VDR. Since we also have shown that VDR, but not NF- ?B -C/EBP¿ transactivities, are suppressed in the epidermis under stressed conditions, both mechanisms are likely coordinately regulated to maintain CAMP expression under basal vs. stressed conditions, respectively. We further showed that S. aureus likely subverts S1P-induced upregulation of CAMP by secreting a neutral sphingomyelinase (SMase) (= ¿-hemolysin) that preferentially diverts newly-generated Cer to glucosylCer (and sphingomyelin), which we hypothesize would simultaneously diminish S1P production, in parallel with a failure of sustained CAMP uperegulation. Cer and/or S1P could also upregulate ABCA12, a transporter protein that is likely required for CAMP secretion, via PPAR¿/¿ activation. In this proposal, we will investigate 1) the coordinate regulation of CAMP expression/secretion via VDR and NF- ?B -C/EBP¿ mechanisms under basal vs. stressed conditions; 2) how a S. aureus virulence factor subverts the Cer->S1P signaling of CAMP production; and 3) novel, readily- translatable therapeutic approaches that both interdict the S. aureus virulence mechanism and enhance S1P signaling of CAMP production and/or secretion in normal and AD skin.
描述(由适用提供):特应性皮炎(AD)皮肤显示表皮渗透性以及抗菌缺乏症,并且经常用强烈的金黄色葡萄球菌定植。神经酰胺(CER)既是必不可少的渗透性屏障脂质物种,又是一个生物效应器,可以改变核表皮角质形成细胞(KC)中多个细胞功能。重要的是,有所不同 CER的代谢产物,鞘氨醇1-磷酸(S1P)也可以调节细胞功能,并且AD中CER和S1P的水平均降低。与该提案有关,AD表皮显示未能上调主要表皮cathelicidin抗菌肽(CAMP)/LL-37表达,这可能解释了金黄色葡萄球菌的定殖和AD中的持久性。最近,我们证明了S1P不仅通过特征良好的维生素D接收器(VDR)依赖性机制刺激cAMP表达,而且还通过NF-?B-C/EBP? - 依赖性途径,与VDR无关。由于我们还表明,在压力条件下,在表皮中抑制了VDR,但不具有NF-?B -C/EBP启动性,因此两种机制可能分别协调地调节以在低音与压力条件下保持cAMP表达。我们进一步表明,金黄色葡萄球菌可能通过分泌中性鞘磷脂酶(Smase)(=�-甲状腺素)而优先将新生成的CER转移到葡萄糖基酯(和鞘磷脂)的情况下,我们可以简单地将S1P的S1P生产下降,从而颠覆了S1P诱导的CAMP上调(=�-Hemolysin)。 CER和 /或S1P还可以上调ABCA12,ABCA12是一种通过pPAR® /¿激活而可能需要的转运蛋白。在此提案中,我们将研究1)在基本与压力条件下,通过VDR和NF-?B -C/EBP。机制对CAMP表达/分泌的坐标调节; 2)金黄色葡萄球菌病毒因子如何颠覆营地生产的CER-> S1P信号; 3)新颖的,很容易翻译的治疗方法,既禁止金黄色葡萄球菌病毒机制,又增强了正常和AD皮肤中cAMP生产和/或分泌的S1P信号传导。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YOSHIKAZU UCHIDA其他文献

YOSHIKAZU UCHIDA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YOSHIKAZU UCHIDA', 18)}}的其他基金

S1P-Mediated Stimulation of Antimicrobial Defense
S1P 介导的抗菌防御刺激
  • 批准号:
    8368507
  • 财政年份:
    2012
  • 资助金额:
    $ 32.68万
  • 项目类别:
S1P-Mediated Stimulation of Antimicrobial Defense
S1P 介导的抗菌防御刺激
  • 批准号:
    8507601
  • 财政年份:
    2012
  • 资助金额:
    $ 32.68万
  • 项目类别:
S1P-Mediated Stimulation of Antimicrobial Defense
S1P 介导的抗菌防御刺激
  • 批准号:
    8852551
  • 财政年份:
    2012
  • 资助金额:
    $ 32.68万
  • 项目类别:
Epidermal Mechanisms Opposing Ceramide-Induced Apoptosis
表皮机制对抗神经酰胺诱导的细胞凋亡
  • 批准号:
    7169801
  • 财政年份:
    2005
  • 资助金额:
    $ 32.68万
  • 项目类别:
Epidermal Mechanisms Opposing Ceramide-Induced Apoptosis
表皮机制对抗神经酰胺诱导的细胞凋亡
  • 批准号:
    7345475
  • 财政年份:
    2005
  • 资助金额:
    $ 32.68万
  • 项目类别:
Epidermal Mechanisms Opposing Ceramide-Induced Apoptosis
表皮机制对抗神经酰胺诱导的细胞凋亡
  • 批准号:
    6872629
  • 财政年份:
    2005
  • 资助金额:
    $ 32.68万
  • 项目类别:
Epidermal Mechanisms Opposing Ceramide-Induced Apoptosis
表皮机制对抗神经酰胺诱导的细胞凋亡
  • 批准号:
    7002745
  • 财政年份:
    2005
  • 资助金额:
    $ 32.68万
  • 项目类别:
Epidermal Mechanisms Opposing Ceramide-Induced Apoptosis
表皮机制对抗神经酰胺诱导的细胞凋亡
  • 批准号:
    7565977
  • 财政年份:
    2005
  • 资助金额:
    $ 32.68万
  • 项目类别:

相似海外基金

S1P-Mediated Stimulation of Antimicrobial Defense
S1P 介导的抗菌防御刺激
  • 批准号:
    8368507
  • 财政年份:
    2012
  • 资助金额:
    $ 32.68万
  • 项目类别:
S1P-Mediated Stimulation of Antimicrobial Defense
S1P 介导的抗菌防御刺激
  • 批准号:
    8507601
  • 财政年份:
    2012
  • 资助金额:
    $ 32.68万
  • 项目类别:
Structural Dynamics of Multi-drug Transporters
多药物转运蛋白的结构动力学
  • 批准号:
    8122512
  • 财政年份:
    2006
  • 资助金额:
    $ 32.68万
  • 项目类别:
Structural Dynamics of Multi-drug Transporters
多药物转运蛋白的结构动力学
  • 批准号:
    8044156
  • 财政年份:
    2006
  • 资助金额:
    $ 32.68万
  • 项目类别:
Structural Dynamics of Multi-drug Transporters
多药物转运蛋白的结构动力学
  • 批准号:
    8445258
  • 财政年份:
    2006
  • 资助金额:
    $ 32.68万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了